SGLT‐2 Inhibitors Use in Hospitalized Patients in France: A Cross‐Sectional Study

Documenti analoghi

• Second primary cancers and hormonal therapies for prostate cancer: A nested case–control study
  di: Lucie‐Marie Scailteux, et al.
  Pubblicazione: (2025)
• Appropriateness of oxycodone use for acute pain in surgical and obstetric departments using a clinical data warehouse
  di: Fabien Xuereb, et al.
  Pubblicazione: (2025)
• Factors Associated With Cocaine Use Disorder: Results From the French Nationwide Repeated Cross‐Sectional OPPIDUM Study (2019–2023)
  di: Zenab Alhamidi, et al.
  Pubblicazione: (2026)
• Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024
  di: Cécile Chevallier, et al.
  Pubblicazione: (2026)
• Sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) plus glucagon‐like peptide type 1 receptor combination is more effective than SGLT2i plus dipeptidyl peptidase‐4 inhibitor combination in treating obese mice metabolic dysfunction‐associated steatotic liver disease (MASLD)
  di: Pedro H. Reis‐Barbosa, et al.
  Pubblicazione: (2024)